MMWR Morb Mortal Wkly Rep. 2020 Feb 7;69(5):125-129. doi: 10.15585/mmwr.mm6905a2.
Increased prevalence of illicitly manufactured fentanyl and fentanyl analogs has contributed substantially to overdose deaths in the United States (1-3). On October 26, 2015, CDC issued a Health Advisory regarding rapid increases in deaths involving fentanyl. This CDC Health Advisory has been updated twice to address increases in fentanyl and fentanyl analog overdoses and their co-occurrence with nonopioids (4). Deaths involving carfentanil, an analog reportedly 10,000 times more potent than morphine and 100 times more potent than fentanyl, were first reported in Florida, Michigan, and Ohio in 2016 and described in an August 2016 CDC Health Advisory (1,5). Carfentanil is used to rapidly immobilize large animals in veterinary medicine and has no U.S. approved therapeutic use in humans. Carfentanil's street price per dose is likely lower than that of heroin. During 2016 and 2017, an outbreak of carfentanil-involved fatal overdoses in Florida emerged, and the Medical Examiner jurisdiction serving Sarasota, Manatee, and DeSoto counties (the Sarasota area) was the outbreak epicenter. This report describes toxicology profiles, sociodemographic information, and geographic distributions of carfentanil-involved fatal overdoses (carfentanil deaths) in the Sarasota area compared with those in the rest of Florida (i.e., all Florida counties excluding Sarasota area) from January 2016 to December 2017. The Sarasota area accounted for 19.0% of 1,181 statewide carfentanil deaths that occurred during this time and experienced a peak in carfentanil deaths preceding the larger Florida outbreak. The report of a single carfentanil death from August to December 2017 (compared with 73 reported deaths during the same period in 2016) appeared to mark the end of the outbreak in the area. The threat of such rapid, intense fatal overdose outbreaks highlights the need for accelerated reporting, reliable data sharing systems, and novel proactive surveillance to support targeted prevention and response efforts by public health and safety organizations (6).
在美国,非法制造的芬太尼和芬太尼类似物的流行率不断上升,这在很大程度上导致了过量死亡(1-3)。2015 年 10 月 26 日,疾病预防控制中心发布了一份关于芬太尼导致的死亡人数迅速增加的健康咨询报告。此后,该健康咨询报告已更新了两次,以应对芬太尼和芬太尼类似物过量使用及其与非阿片类药物同时出现的情况(4)。2016 年,佛罗里达州、密歇根州和俄亥俄州首次报告了卡芬太尼(一种据报道比吗啡强 10000 倍、比芬太尼强 100 倍的类似物)导致的死亡病例,并在 2016 年 8 月的疾病预防控制中心健康咨询报告中对此进行了描述(1,5)。卡芬太尼在兽医领域用于快速使大型动物失去活动能力,在美国没有批准用于人体治疗。卡芬太尼的每剂街头价格可能低于海洛因。2016 年和 2017 年期间,佛罗里达州出现了与卡芬太尼有关的致命过量用药爆发事件,为萨拉索塔、马纳提和迪索托县提供法医服务的萨拉索塔地区(萨拉索塔地区)是此次爆发的中心。本报告描述了 2016 年 1 月至 2017 年 12 月期间萨拉索塔地区与佛罗里达州其他地区(即除萨拉索塔地区外的佛罗里达州所有县)的卡芬太尼致死过量用药(卡芬太尼死亡)的毒理学特征、社会人口学信息和地理分布情况。在这段时间里,萨拉索塔地区占全州 1181 例卡芬太尼死亡病例的 19.0%,并且在佛罗里达州更大规模的爆发之前,卡芬太尼死亡人数达到了峰值。2017 年 8 月至 12 月期间,仅报告了 1 例卡芬太尼死亡病例(而 2016 年同期报告了 73 例死亡病例),这似乎标志着该地区疫情的结束。此类快速、剧烈的致命过量用药爆发的威胁凸显了加快报告、可靠的数据共享系统和新的主动监测的必要性,以支持公共卫生和安全组织有针对性的预防和应对工作(6)。